{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:13Z","timestamp":1789578313597,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Johnson & Johnson Innovative Medicine","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004331","name":"Johnson and Johnson","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.06.003","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T22:27:58Z","timestamp":1784068078000},"page":"977-985","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting"],"prefix":"10.1016","volume":"9","author":[{"given":"Eva M.","family":"Comp\u00e9rat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui Pedro","family":"Caetano Moreira Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Chiappetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farah","family":"Hodeib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hubank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas","family":"Kl\u00fcmper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Penault-Llorca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Rijken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst-Jan M.","family":"Speel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadett","family":"Szabados","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle Vanden","family":"Bempt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geert J.L.H.","family":"Van Leenders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariavittoria","family":"Vescovo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.06.003_b0005","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","article-title":"Bladder cancer","volume":"9","author":"Dyrskj\u00f8t","year":"2023","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.euo.2026.06.003_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102530","article-title":"Role of FGFR3 in bladder cancer: treatment landscape and future challenges","volume":"115","author":"Ascione","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.euo.2026.06.003_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.humpath.2021.04.001","article-title":"Molecular pathology of urothelial carcinoma","volume":"113","author":"Lopez-Beltran","year":"2021","journal-title":"Hum Pathol"},{"key":"10.1016\/j.euo.2026.06.003_b0020","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.euo.2026.06.003_b0025","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2026.06.003_b0030","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.06.003_b0035","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.eururo.2020.07.018","article-title":"Fibroblast growth factor receptor 3 alteration status is associated with differential sensitivity to platinum-based chemotherapy in locally advanced and metastatic urothelial carcinoma","volume":"78","author":"Teo","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.003_b0040","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.pharmthera.2017.05.013","article-title":"Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach","volume":"179","author":"Presta","year":"2017","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.euo.2026.06.003_b0045","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.euo.2026.06.003_b0050","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1158\/1535-7163.MCT-16-0518","article-title":"Oncogenic characterization and pharmacologic sensitivity of activating fibroblast growth factor receptor (FGFR) genetic alterations to the selective FGFR inhibitor erdafitinib","volume":"16","author":"Karkera","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.euo.2026.06.003_b0055","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.003_b0060","unstructured":"European Association of Urology (EAU). Guidelines; 2025. https:\/\/uroweb.org\/guidelines."},{"key":"10.1016\/j.euo.2026.06.003_b0065","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.003_b0070","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. NCCN Guidelines. Bladder Cancer. version 3.2024; 2024."},{"key":"10.1016\/j.euo.2026.06.003_b0075","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.3390\/ijms25063319","article-title":"Accelerated aging in cancer survivors: cellular senescence, frailty, and possible opportunities for interventions","volume":"25","author":"Wang","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.euo.2026.06.003_b0080","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41585-024-00951-2","article-title":"Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer","volume":"22","author":"Kl\u00fcmper","year":"2024","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2026.06.003_b0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.euo.2026.06.003_b0090","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00345-021-03831-1","article-title":"Updated pathology reporting standards for bladder cancer: biopsies, transurethral resections and radical cystectomies","volume":"40","author":"Comp\u00e9rat","year":"2022","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2026.06.003_b0095","series-title":"Adequate tissue for adequate diagnosis: what do we really need? Lung cancer","first-page":"119","author":"Roemen","year":"2015"},{"key":"10.1016\/j.euo.2026.06.003_b0100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00428-022-03343-2","article-title":"Expert opinion on NSCLC small specimen biomarker testing \u2013 Part 1: tissue collection and management","volume":"481","author":"Penault-Llorca","year":"2022","journal-title":"Virchows Arch"},{"key":"10.1016\/j.euo.2026.06.003_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103682","article-title":"New emerging targets in advanced urothelial carcinoma: is it the primetime for personalized medicine?","volume":"174","author":"Audisio","year":"2022","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"10.1016\/j.euo.2026.06.003_b0110","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.003_b0115","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1093\/annonc\/mdy263","article-title":"A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)","volume":"29","author":"Mateo","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.003_b0120","series-title":"P5 eHealth: An agenda for the health technologies of the future","first-page":"125","article-title":"Role of next-generation sequencing technologies in personalized medicine","author":"Morganti","year":"2020"},{"key":"10.1016\/j.euo.2026.06.003_b0125","series-title":"IASLC atlas of molecular testing for targeted therapy in lung cancer","author":"Sholl","year":"2023"},{"key":"10.1016\/j.euo.2026.06.003_b0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113368","article-title":"Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer","volume":"195","author":"Helal","year":"2023","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.euo.2026.06.003_b0135","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12943-022-01543-7","article-title":"Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments","volume":"21","author":"Lone","year":"2022","journal-title":"Mol Cancer"},{"key":"10.1016\/j.euo.2026.06.003_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlb.2025.100310","article-title":"Liquid biopsy: current advancements in clinical practice for bladder cancer","volume":"9","author":"Crocetto","year":"2025","journal-title":"J Liq Biopsy"},{"key":"10.1016\/j.euo.2026.06.003_b0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/cancers16040803","article-title":"New perspectives on the role of liquid biopsy in bladder cancer: applicability to precision medicine","volume":"16","author":"Alberca-del Arco","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.euo.2026.06.003_b0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111859","article-title":"Genomic heterogeneity as a barrier to precision oncology in urothelial cancer","volume":"41","author":"Clinton","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.euo.2026.06.003_b0155","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1038\/s41467-024-55331-6","article-title":"AI allows pre-screening of FGFR3 mutational status using routine histology slides of muscle-invasive bladder cancer","volume":"15","author":"Bannier","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.003_b0160","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.euf.2021.04.007","article-title":"Artificial intelligence-based detection of FGFR3 mutational status directly from routine histology in bladder cancer: a possible preselection for molecular testing?","volume":"8","author":"Loeffler","year":"2022","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.06.003_b0165","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1038\/s41467-024-49153-9","article-title":"Development and deployment of a histopathology-based deep learning algorithm for patient prescreening in a clinical trial","volume":"15","author":"Juan Ramon","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.euo.2026.06.003_b0170","unstructured":"Erdafitinib summary of product characteristics. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/balversa-epar-product-information_en.pdf."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:32Z","timestamp":1789577192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001719"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR3 Testing in Urothelial Carcinoma: An Expert Commentary on Best Practices From Patient Identification to Result Reporting","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Johnson & Johnson Innovative Medicine. Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}